~~<i id='4C2F1D112A'><strike id='4C2F1D112A'><tt id='4C2F1D112A'><pre id='4C2F1D112A'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-09-28 03:31:38 Page View：6266

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Vermont grapples with historic flooding as more rainstorms head for Northeast
Next article： Peter Hotez and the public health issue of online harassment

comprehensive

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

H5N1 bird flu virus started spreading in cows in Texas in December

ColorizedmicroscopicimageofH5N1birdfluvirusparticles(inyellow).NIAIDAsagriculturalauthoritiesandepid

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Getting Alzheimer's drug Leqembi to patients can be a challenge

BenMargot/APAhostofhurdlesareslowingtheadoptionofthenewAlzheimer’sdrugLeqembi,expertsinvolvedinthetr